JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

Diagnosis, Management and Pathophysiology of Polycystic Ovarian Syndrome

Meghana A[1], Dhana Lakshmi G*[2], Durga Naresh Kumar G[1], Anusha G[1], Gangadhar J[1], Naga Lakshmi A[1]

[1] *UG Scholar, Department of Pharmacology, Koringa College of Pharmacy, Korangi, Kakinada, Andhra Pradesh, India*
[2] *Associate Professor Department of Pharmacology, Koringa College of Pharmacy, Korangi, Kakinada, Andhra Pradesh, India*

Publication history: Received on 17th November 2025; Revised on 27th December 2025; Accepted on 2nd January 2026

Article DOI: 10.69613/e52arj05

Abstract: Polycystic Ovarian Syndrome (PCOS) is a pervasive endocrine disturbance affecting approximately 8% to 13% of women in their reproductive prime, characterized by a heterogeneous constellation of hyperandrogenism, ovulatory dysfunction, and distinct ovarian morphology. The condition occurs due to multiple factors like polygenic susceptibility and environmental triggers, leading to a state of chronic low-grade inflammation and metabolic disarray. Central to its development are the synergistic effects of neuroendocrine irregularities, specifically increased gonadotropin-releasing hormone pulse frequency, and peripheral insulin resistance. These mechanisms cause ovarian theca cell hyperplasia and excessive androgen synthesis, which in turn arrest follicular maturation and precipitate the characteristic polycystic appearance. Apart from its reproductive implications, the syndrome acts as a significant risk factor for type 2 diabetes mellitus, cardiovascular disease, and endometrial neoplasia. Diagnosis necessitated by the Rotterdam criteria requires the exclusion of mimicking pathologies such as congenital adrenal hyperplasia and hyperprolactinemia. Management strategies have transitioned from purely symptomatic relief toward holistic models that prioritize aggressive lifestyle modification alongside targeted pharmacological interventions. The combination of insulin sensitizers, anti-androgens, and newer metabolic agents like GLP-1 receptor agonists reflects an evolving therapeutic paradigm aimed at mitigating long-term systemic complications. Early identification and a multi-disciplinary healthcare remain paramount in improving the metabolic and psychological trajectory of affected individuals throughout their lifespan.

Keywords: Hyperandrogenism; Insulin Resistance; Anovulation; Rotterdam Criteria; Metabolic Syndrome

1. Introduction

Polycystic Ovarian Syndrome (PCOS) is identified as the most frequent endocrinopathy among women of reproductive age, presenting a significant challenge to global public health due to its multi-systemic impact [1]. Current epidemiological data suggest a prevalence ranging from 8% to 13%, though these figures increase substantially to nearly 20% when applying broader diagnostic frameworks. The burden of the condition extends beyond individual health, impacting socioeconomic structures through increased healthcare utilization and long-term disability related to metabolic comorbidities. It remains a focal point of reproductive medicine as a leading cause of anovulatory infertility, yet its reach encompasses the entire physiological spectrum from neuroendocrine regulation to peripheral tissue metabolism [1].

Initially perceived as a localized gynecological issue primarily involving the presence of ovarian "cysts," it is now recognized as a complex metabolic-endocrine disorder with roots in genetic predisposition and epigenetic modifications influenced by lifestyle factors [2]. This transition in conceptualization reflects an increased appreciation for the developmental origins of the syndrome. Genomic studies have identified multiple susceptibility loci associated with steroidogenesis and insulin signaling, yet the phenotypic expression is heavily modulated by environmental triggers. In utero exposure to androgen excess and postnatal nutritional habits appear to play a critical role in the epigenetic programming of the disorder, creating a lifelong susceptibility that often manifests during the pubertal transition [2].

The prevalence of the condition varies significantly across different ethnic groups and is notably higher in populations with rising obesity rates, which serves to exacerbate the underlying hormonal imbalances [3]. Research indicates that South Asian and Hispanic women often exhibit more severe metabolic phenotypes and higher degrees of insulin resistance at lower body mass index (BMI) thresholds compared to their Caucasian counterparts. Conversely, African American women frequently present with a higher incidence of cardiovascular risk factors and hypertension associated with the syndrome. The modern "obesogenic" environment, characterized by sedentary behavior and high-caloric intake, acts as a catalyst, unmasking latent genetic vulnerabilities and accelerating the progression of the disease [3].

* Corresponding author: Dhana Lakshmi G

Copyright © 2026 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0.

The clinical hallmark involves a disruption of the hypothalamic-pituitary-ovarian axis, resulting in persistent biochemical or clinical hyperandrogenism and menstrual irregularities [4]. Central to this dysfunction is an increased frequency of the hypothalamic gonadotropin-releasing hormone (GnRH) pulse generator, which promotes excessive luteinizing hormone (LH) secretion while limiting follicle-stimulating hormone (FSH) production. This hormonal skewing prevents the selection of a dominant follicle and facilitates the arrest of multiple small follicles in the antral stage. The resulting chronic anovulation leads to prolonged periods of estrogen exposure without the cyclic protection of progesterone, creating a state of hormonal flux that characterizes the PCOS phenotype [4].

Affected individuals often present with a spectrum of symptoms ranging from dermatological concerns like acne and hirsutism to profound reproductive challenges, including subfertility and recurrent pregnancy loss [5]. Hirsutism, often assessed via the modified Ferriman-Gallwey score, affects up to 70% of those diagnosed and serves as a significant source of psychological morbidity. Beyond these surface manifestations, the reproductive environment is often compromised by poor oocyte quality and an unreceptive endometrial lining, contributing to lower live birth rates and a heightened risk of obstetric complications such as preeclampsia and gestational diabetes [5].

The metabolic sequelae, particularly insulin resistance and compensatory hyperinsulinemia, create a feedback loop that sustains ovarian androgen overproduction and contributes to dyslipidemia and glucose intolerance [6]. Insulin acts as a co-gonadotropin, directly stimulating theca cell steroidogenesis and inhibiting the hepatic production of sex hormone-binding globulin (SHBG). This results in a surge of bioavailable testosterone, which further impairs insulin sensitivity in a vicious cycle. Over time, this state of chronic hyperinsulinemia predisposes individuals to metabolic syndrome, non-alcoholic fatty liver disease, and early-onset atherosclerosis [6].

Given its lifelong implications, transitioning from adolescent-onset to post-menopausal metabolic risks, the necessity for a standardized yet individualized approach to diagnosis and therapy is critical for optimizing patient outcomes [7]. While the reproductive issues may dominate early clinical interactions, the later stages of life are marked by an escalating risk of type 2 diabetes and endometrial adenocarcinoma. Therefore, clinicians must adopt a longitudinal care model that prioritizes early detection and continuous metabolic surveillance to improve the overall health trajectory of those affected by this heterogeneous condition [7].

2. Pathophysiology of Polycystic Ovarian Syndrome

The etiology of the syndrome is multifactorial, involving a synergistic relationship between genetic susceptibility, neuroendocrine dysfunction, and metabolic triggers. It is generally categorized as a complex trait where multiple risk alleles interact with environmental factors such as diet, physical activity levels, and exposure to endocrine-disrupting chemicals [8].

2.1. Genetic and Epigenetic Factors

Research indicates a strong familial clustering, suggesting a polygenic inheritance pattern. Specific genetic loci associated with gonadotropin secretion, insulin signaling, and androgen biosynthesis particularly those located on chromosomes 2 and 9 have been implicated in increasing susceptibility [9]. Epigenetic modifications, potentially occurring in utero due to maternal androgen excess, may also program the fetus for a PCOS phenotype in later life, highlighting the developmental origins of the disorder [10, 11].

2.2. Neuroendocrine Dysfunction

A primary driver in the pathophysiology is the alteration in the hypothalamic gonadotropin-releasing hormone (GnRH) pulse generator.

2.2.1. Alterations in GnRH Pulse Frequency

In affected individuals, there is a persistent increase in the frequency of GnRH pulses, which preferentially stimulates the anterior pituitary to secrete Luteinizing Hormone (LH) while relatively suppressing Follicle-Stimulating Hormone (FSH) [12, 13]. This results in an elevated LH-to-FSH ratio, typically observed as 2:1 or 3:1 in clinical assessments. The relative deficiency of FSH hinders the induction of the aromatase enzyme within granulosa cells, preventing the conversion of androgens to estrogens and leading to an accumulation of intrafollicular androgens [14, 15].

2.2.2. The Role of Luteinizing Hormone

Chronic elevation of LH acts directly on the ovarian theca cells, which undergo hyperplasia. These cells become hyper-responsive to LH stimulation, significantly increasing the production of androstenedione and testosterone. The absence of a mid-cycle LH

surge, caused by the lack of appropriate estrogenic feedback, results in chronic anovulation and the formation of numerous sub-centimeter follicles that fail to reach dominance [16, 17].



Figure 1. Pathophysiology of PCOS

Table 1. Evolution of Diagnostic Criteria for PCOS

Feature	NIH (1990)	Rotterdam (2003)	AE-PCOS Society (2006)
Hyperandrogenism	Mandatory (Clinical or Biochemical)	1 of 3 (Optional if others present)	Mandatory (Clinical or Biochemical)
Ovulatory Dysfunction	Mandatory (Oligo/Anovulation)	1 of 3 (Optional if others present)	1 of 2 (Optional if PCOM present)
Polycystic Ovaries (PCOM)	Not Included	1 of 3 (Optional if others present)	1 of 2 (Optional if Dysfunction present)
Requirement	Both features must be present	2 out of 3 features required	Hyperandrogenism + 1 other feature

2.3. Mechanisms of Hyperandrogenism

Hyperandrogenism is the central biochemical feature, derived primarily from the ovaries with a minor contribution from the adrenal glands.

2.3.1. Ovarian Androgen Excess

Theca cells in the PCOS ovary demonstrate an intrinsic over-expression of steroidogenic enzymes, such as CYP17A1. This enzymatic hyperactivity, combined with LH overstimulation and hyperinsulinemia, leads to serum testosterone levels that frequently exceed 70 ng/dL [17]. These elevated androgens exert a "folliculotoxic" effect, arresting the growth of primary follicles and preventing their maturation into Graafian follicles [18].

2.3.2. Adrenal Contribution

In approximately 20% to 30% of cases, there is a concomitant increase in adrenal androgens, specifically Dehydroepiandrosterone sulfate (DHEA-S). This suggests that the generalized dysregulation of the cytochrome P450 system and heightened sensitivity to Adrenocorticotropic Hormone (ACTH) may play a secondary role in the hyperandrogenic state [17].

2.4. Metabolic Interplay and Insulin Resistance

Insulin resistance (IR) is a fundamental component of the syndrome, present in both obese and lean phenotypes, although obesity significantly exacerbates its severity.

2.4.1. Peripheral Insulin Resistance

The resistance is characterized by post-receptor signaling defects in skeletal muscle and adipose tissue, leading to compensatory hyperinsulinemia. Interestingly, while these tissues are resistant to glucose uptake, the ovaries remain sensitive to the mitogenic and steroidogenic actions of insulin. Hyperinsulinemia acts synergistically with LH to augment theca cell androgen production and simultaneously suppresses the hepatic synthesis of Sex Hormone-Binding Globulin (SHBG) [16]. The reduction in SHBG increases the fraction of free, biologically active testosterone in the circulation, worsening clinical symptoms [12].

2.4.2. Impact of Obesity

Obesity is prevalent in 40% to 80% of individuals with the syndrome and serves as a significant aggravator of the phenotype. Adipose tissue, particularly visceral fat, functions as an active endocrine organ that secretes pro-inflammatory cytokines and adipokines, further impairing insulin sensitivity [19]. Additionally, fat cells contain the aromatase enzyme, which converts androgens to estrone (E1). The resulting high levels of E1, in the absence of progesterone, lead to endometrial hyperplasia and irregular, breakthrough uterine bleeding [15, 16].

2.5. Folliculogenesis and Ovarian Morphology

The culmination of these hormonal imbalances leads to a defect in folliculogenesis. The arrest of follicles at the pre-antral and early antral stages (2–9 mm) gives the ovary its characteristic polycystic appearance on ultrasound. This morphology is not representative of true cysts but rather a surplus of immature follicles that are unable to proceed to ovulation due to the hostile, androgen-dominant environment [18].

3. Diagnosis and Clinical Evaluation

The identification of Polycystic Ovarian Syndrome requires a meticulous integration of clinical, biochemical, and sonographic evidence. Because the syndrome mimics several other endocrine disorders, a diagnosis of exclusion is mandatory to ensure clinical accuracy [5].

3.1. Standardized Diagnostic Criteria

The Rotterdam criteria, established in 2003 and reaffirmed by subsequent international consensus, remain the gold standard. A diagnosis is confirmed when at least two of the following three features are present, provided other etiologies are excluded [7, 8]:

3.1.1. Clinical or Biochemical Hyperandrogenism

Clinical hyperandrogenism is typically assessed using the Ferriman-Gallwey score for hirsutism, alongside evaluations for acne and androgenic alopecia. Biochemical hyperandrogenism is defined by elevated levels of serum total or free testosterone, or dehydroepiandrosterone sulfate (DHEA-S). It is recommended that these biochemical assessments be performed during the early follicular phase, particularly in women with regular cycles [9].

Table 2. Biochemical and Hormonal Profile Alterations in PCOS

Parameter	Typical Trend	Clinical Significance
Total/Free Testosterone	↑	Drivers of hirsutism, acne, and follicular arrest.
LH:FSH Ratio	↑ (2:1 to 3:1)	Preferential LH secretion; triggers theca cell androgen synthesis.
SHBG	↓	Reduces androgen binding; increases free (bioavailable) testosterone.
Fasting Insulin	↑	Compensatory hyperinsulinemia due to peripheral resistance.
AMH (Anti-Müllerian Hormone)	↑	Reflects increased antral follicle count; inhibits FSH sensitivity.
DHEA-S	↑ (30% of cases)	Indicates adrenal contribution to hyperandrogenic state.

3.1.2. Ovulatory Dysfunction

This manifests as oligomenorrhea (cycles longer than 35 days) or amenorrhea (absence of menstruation for over three months). Even in women with seemingly regular cycles, chronic anovulation may be present, necessitating serum progesterone testing during the mid-luteal phase [13].



Figure 2. Diagnosis of PCOS

3.1.3. Polycystic Ovarian Morphology (PCOM)

Sonographic evidence of PCOM is defined by the presence of 12 or more follicles in either ovary, measuring between 2 to 9 mm in diameter, or an increased ovarian volume exceeding 10 cc. Recent advancements in high-frequency transvaginal ultrasound have suggested increasing the threshold to 20 or more follicles to account for improved resolution in modern equipment [7, 10].

3.2. Differential Diagnosis and Exclusion of Mimics

To finalize a diagnosis, clinicians must rule out late-onset congenital adrenal hyperplasia (CAH), Cushing's syndrome, and hyperprolactinemia.

3.2.1. Screening for Congenital Adrenal Hyperplasia

Late-onset 21-hydroxylase deficiency presents with similar hyperandrogenic symptoms. Measuring morning 17-hydroxyprogesterone (17-OHP) is the primary screening tool. Values below 200 ng/dL generally exclude CAH, whereas values between 200–800 ng/dL warrant an ACTH stimulation test for confirmation [9, 10].

3.2.2. Secondary Amenorrhea Evaluation

In cases of secondary amenorrhea, a pregnancy test is the first mandatory step. Subsequent hormonal panels should include Thyroid-Stimulating Hormone (TSH) and Prolactin to rule out thyroid dysfunction or prolactinomas. A progesterone challenge test can be utilized to assess endogenous estrogen levels and the patency of the outflow tract; withdrawal bleeding typically supports a PCOS diagnosis [13].

4. Clinical Complications and Health Implications

The syndrome presents a spectrum of both immediate and delayed health risks, necessitating a longitudinal approach to patient care [11].

4.1. Short-term Clinical Manifestations

Initial concerns often center on dermatological and reproductive health. Hirsutism, persistent acne, and male-pattern alopecia are frequently reported and contribute significantly to psychological distress. Infertility due to chronic anovulation is the primary reason for clinical presentation in reproductive-aged women. The persistent high levels of LH and androgen excess interfere with normal follicle selection, creating a self-perpetuating cycle of reproductive dysfunction [11, 14].



Figure 3. Long-term Complications in PCOS

Table 3. Systemic Complications Categorized by Clinical Domain

Category	Complication	Temporal Nature	Impact/Risk
Dermatological	Hirsutism, Acne, Alopecia	Short-term/Chronic	High psychological and cosmetic burden.
Reproductive	Anovulatory Infertility	Short-term	Primary cause of subfertility in PCOS.
Obstetric	Gestational Diabetes, Pre-eclampsia	Acute/Pregnancy	Increased risk of preterm birth and NICU admission.
Metabolic	Type 2 Diabetes, Metabolic Syndrome	Long-term	4-fold increase in risk compared to healthy controls.
Cardiovascular	Dyslipidemia, Hypertension, CAD	Long-term	Early-onset atherosclerosis and myocardial infarction.
Oncological	Endometrial Adenocarcinoma	Long-term	Secondary to chronic unopposed estrogenic stimulation.

4.2. Long-term Systemic Risks

The metabolic disturbances associated with the condition have profound implications beyond the reproductive years.

4.2.1. Metabolic and Cardiovascular Disease

Individuals with the syndrome are at a fourfold increased risk of developing type 2 diabetes mellitus due to persistent insulin resistance. Dyslipidemia characterized by elevated Low-Density Lipoprotein (LDL) and reduced High-Density Lipoprotein (HDL)

alongside hypertension, significantly raises the risk of early-onset coronary artery disease and myocardial infarction [11, 12]. Non-alcoholic steatohepatitis (NASH) and obstructive sleep apnea are also frequently associated with the obese phenotype [11, 20].

4.2.2. Cancer

Chronic anovulation leads to a state of "unopposed estrogen," where the endometrium is stimulated by estrogen without the protective effect of progesterone. This significantly increases the risk of endometrial hyperplasia and, eventually, endometrial adenocarcinoma. Regular monitoring and endometrial biopsy are advised if abnormal uterine bleeding occurs [12].

4.2.3. Obstetric Complications

During pregnancy, affected women face higher rates of gestational diabetes, pregnancy-induced hypertension, and pre-eclampsia. There is also a notable increase in the incidence of preterm births and neonatal intensive care unit admissions [11, 22].

5. Therapeutic Management

Management must be tailored to the individual's primary concerns, whether they involve metabolic health, cycle regulation, or fertility [21].

5.1. Primary Lifestyle Interventions

Weight loss remains the cornerstone of management. A reduction of even 5% to 10% of total body weight has been shown to improve insulin sensitivity, reduce androgen levels, and restore regular ovulation [22].

5.1.1. Nutritional Management

A diet focusing on low glycemic index (GI) foods is recommended to minimize insulin spikes. Anti-inflammatory diets rich in whole grains, lean proteins, and omega-3 fatty acids help mitigate the chronic low-grade inflammation associated with the syndrome [20].

5.1.2. Physical Activity and Stress Reduction

A regimen of 150 minutes of moderate-intensity exercise per week, combining aerobic activity with resistance training, optimizes glucose metabolism. Additionally, stress management through meditation and adequate sleep is vital to regulate cortisol levels, which can otherwise exacerbate hormonal imbalances [20, 21].



Figure 4. Management of PCOS

5.2. Conventional Pharmacological Approaches

Pharmacotherapy is often required to address specific symptoms when lifestyle changes alone are insufficient.

5.2.1. Oral Contraceptive Pills (OCPs)

These are first-line for cycle regulation and hirsutism. They increase SHBG levels, thereby lowering free testosterone, and provide endometrial protection [22].

5.2.2. Insulin Sensitizers

Metformin is widely utilized to improve insulin action, facilitate weight loss, and potentially restore ovulatory function [16].

5.2.3. Anti-Androgens

Agents like Spironolactone or Cyproterone acetate are used as adjuncts to OCPs for managing severe hirsutism and acne, though they require strict contraception due to potential teratogenicity [23, 24].

5.2.4. Ovulation Induction

Letrozole, an aromatase inhibitor, has superseded Clomiphene citrate as the first-line treatment for infertility due to higher live birth rates and a lower incidence of multiple pregnancies [25].

Table 4. Clinical Indications for Pharmacological Interventions

Medication Class	Example Agents	Primary Indication	Mechanism of Action
Combined OCPs	Ethinylestradiol/Drospirenone	Cycle Regulation / Hirsutism	Suppresses LH; increases SHBG; protects endometrium.
Insulin Sensitizers	Metformin	Metabolic Health / Prediabetes	Inhibits hepatic glucose production; improves peripheral sensitivity.
Anti-Androgens	Spironolactone	Hirsutism / Alopecia	Competitively inhibits the androgen receptor.
Aromatase Inhibitors	Letrozole	Infertility (Ovulation Induction)	Suppresses estrogen to trigger a compensatory rise in FSH.
Progestogens	Medroxyprogesterone	Endometrial Protection	Induces withdrawal bleeding; prevents hyperplasia.

5.3. Experimental Treatments

Recent research has shifted toward addressing the underlying metabolic and inflammatory pathways.

5.3.1. Inositol Supplementation

Myo-inositol and D-chiro-inositol act as secondary messengers in insulin signaling. Clinical evidence suggests that a 40:1 ratio of these isomers can significantly improve egg quality and metabolic markers [25].

5.3.2. GLP-1 Receptor Agonists and SGLT2 Inhibitors

Medications like Liraglutide and Semaglutide are showing promise for significant weight reduction and metabolic improvement in PCOS patients with obesity. SGLT2 inhibitors are also being investigated for their ability to reduce androgen levels by promoting glucose excretion, though their use remains experimental [26].

5.3.3. Integrative Therapies

The use of N-acetylcysteine (NAC) and Vitamin D supplementation is gaining traction for reducing oxidative stress and improving follicular development. Low-dose naltrexone is also being explored for its potential to modulate the immune-metabolic axis and reduce chronic inflammation [27].

Table 5. Emerging Therapeutic Agents

Agent	Classification	Primary Clinical Benefit	Status
Myo-Inositol	Insulin Mimetic	Improves oocyte quality; restores cycle regularity.	Clinical Use / Supplement
Liraglutide / Semaglutide	GLP-1 Receptor Agonist	Significant weight reduction; glucose control.	Clinical Use (Off-label/Obesity)
Empagliflozin	SGLT2 Inhibitor	Reduces androgen levels via glucose excretion.	Experimental
N-acetylcysteine (NAC)	Antioxidant	Reduces oxidative stress; improves insulin action.	Integrative / Support
Low-dose Naltrexone	Immune Modulator	Reduces systemic inflammation and LH pulsatility.	Experimental

6. Conclusion

Polycystic Ovarian Syndrome is a multifaceted endocrine and metabolic disturbance that necessitates a shift in clinical perception from a localized reproductive issue to a systemic, lifelong health challenge. The complexity of its pathophysiology involving the synergistic interaction of hypothalamic-pituitary dysfunction, ovarian androgen overproduction, and peripheral insulin resistance underlines the heterogeneity of its clinical presentation. Early identification, particularly during the transition from adolescence, is vital for mitigating immediate dermatological and reproductive concerns while implementing preventative strategies against chronic morbidities. The metabolic sequelae, including an increased propensity for type 2 diabetes and cardiovascular disease, alongside the oncological risk of endometrial adenocarcinoma, demand a longitudinal management model that transcends simple symptom control. Therapeutic success is fundamentally rooted in aggressive lifestyle modification, which serves as the primary intervention for improving insulin sensitivity and restoring ovulatory cycles. The integration of pharmacological agents such as OCPs, metformin, and letrozole remains essential for targeted management; however, the emergence of inositol supplements and GLP-1 receptor agonists offers promising avenues for addressing the deep-seated metabolic disarray characteristic of the syndrome. A multidisciplinary approach involving endocrinologists, gynecologists, nutritionists, and mental health professionals is necessary to provide holistic care that addresses the physical, reproductive, and psychological dimensions of the disorder. Future research must continue to unravel the specific genetic and epigenetic drivers to enable more personalized and effective therapeutic interventions, ultimately improving the quality of life for women across the global population.

References

[1] Joham, A. E., Norman, R. J., Stener-Victorin, E., Legro, R. S., Franks, S., Moran, L. J., ... & Teede, H. J. (2022). Polycystic ovary syndrome. The Lancet Diabetes & Endocrinology, 10(9), 668-680.

[2] Lizneva, D., Suturina, L., Walker, W., Brakta, S., Gavrilova-Jordan, L., & Azziz, R. (2016). Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertility and Sterility, 106(1), 6-15.

[3] March, W. A., Moore, V. M., Willson, K. J., Phillips, D. I., Norman, R. J., & Davies, M. J. (2010). The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Human Reproduction, 25(2), 544-551.

[4] Misso, M., Boyle, J., Norman, R., & Teede, H. (2014). Development of evidenced-based guidelines for PCOS and implications for community health. Seminars in Reproductive Medicine, 32(03), 230-240.

[5] Devi, O. J., Pushpari, C., Manaswini, K., Anjum, S. N., & Lakshmi, V. B. (2021). PCOS: a common but underdiagnosed condition in reproductive women. World Journal of Pharmaceutical Research, 10(7), 598-612.

[6] Gupta, R., & Ahmed, K. M. (2018). Polycystic ovary syndrome research: A scientometric assessment of global publications output during 2007–16. OGH Reports, 7(1).

[7] Rajan, R., Dharman, D., Manohar, D., Dharan, S. S., JR, A., Davis, D. M., & Nair, R. (2020). A cross sectional study of polycystic ovarian syndrome among pharmacy students. International Journal of Research in Clinical and Hospital Pharmacy, 2, 8-11.

[8] Pasquali, R., Stener-Victorin, E., Yildiz, B. O., Duleba, A. J., Hoeger, K., Mason, H., ... & Legro, R. S. (2011). PCOS Forum: research in polycystic ovary syndrome today and tomorrow. Clinical Endocrinology, 74(4), 424-433.

[9] Sadeghi, H. M., Adeli, I., Calina, D., Docea, A. O., Mousavi, T., Daniali, M., ... & Abdollahi, M. (2022). Polycystic ovary syndrome: a comprehensive review of pathogenesis, management, and drug repurposing. International Journal of Molecular Sciences, 23(2), 583.

[10] Deans, R. (2019). Polycystic ovary syndrome in adolescence. Medical Sciences, 7(10), 101.

[11] Hoeger, K. M., Dokras, A., & Piltonen, T. (2021). Update on PCOS: consequences, challenges, and guiding treatment. The Journal of Clinical Endocrinology & Metabolism, 106(3), e1071-e1083.

[12] Carmina, E., & Lobo, R. A. (1999). Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. The Journal of Clinical Endocrinology & Metabolism, 84(6), 1897-1899.

[13] Ajmal, N., Khan, S. Z., & Shaikh, R. (2019). Polycystic ovary syndrome (PCOS) and genetic predisposition: A review article. European Journal of Obstetrics & Gynecology and Reproductive Biology: X, 3, 100060.

[14] Teede, H., Deeks, A., & Moran, L. (2010). Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Medicine, 8(1), 41.

[15] Dutta, D. C. Textbook of Obstetrics Including Perinatology and Contraception. 9th Edition. Jaypee Brothers Medical Publishers.

[16] Seshadri, L. Essentials of Gynaecology. 2nd Edition. Wolters Kluwer India.

[17] El Hayek, S., Bitar, L., Hamdar, L. H., Mirza, F. G., & Daoud, G. (2016). Poly cystic ovarian syndrome: an updated overview. Frontiers in Physiology, 7, 124.

[18] Azziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., ... & Witchel, S. F. (2006). Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. The Journal of Clinical Endocrinology & Metabolism, 91(11), 4237-4245.

[19] Lim, S. S., Davies, M. J., Norman, R. J., & Moran, L. J. (2012). Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction Update, 18(6), 618-637.

[20] Plowden, T. C. (2016). MPH Reproductive endocrinology and infertility. Eunice Kennedy Shriver National Institute of Child Health and Human Development.

[21] Bacchus, H. (2012). Essentials of Gynecologic and Obstetric Endocrinology. Springer Science & Business Media.

[22] Witchel, S. F., Oberfield, S. E., & Peña, A. S. (2019). Polycystic ovary syndrome: pathophysiology, presentation, and treatment with emphasis on adolescent girls. Journal of the Endocrine Society, 3(8), 1545-1573.

[23] Escobar-Morreale, H. F. (2018). Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nature Reviews Endocrinology, 14(5), 270-284.

[24] Diamanti-Kandarakis, E., Kouli, C. R., Bergiele, A. T., et al. (1999). A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. The Journal of Clinical Endocrinology & Metabolism, 84(11), 4006-4011.

[25] Dunaif, A., Given, J., & Haseltine, F. (1992). Diagnostic criteria for Polycystic ovary syndrome: towards a rational approach. Polycystic Ovary Syndrome, Boston, 377-384.

[26] Bako, A. U., Morad, S., & Atiomo, W. A. (2005). Polycystic ovary syndrome: an overview. Reviews in Gynaecological Practice, 5(2), 115-122.

[27] Felemban, A., Tan, S. L., & Tulandi, T. (2000). Laparoscopic treatment of polycystic ovaries with insulated needle cautery: a reappraisal. Fertility and Sterility, 73(2), 266-269.